Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132481 | 0.78 | USP2 (0.37) | USP2ALOX15 | |
| SCHEMBL19957338 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CHRNB2CHRNB4CHRNA4OPRM1 | |
| SCHEMBL207502 | 0.76 | — | — | |
| SCHEMBL13114038 | 0.76 | — | — | |
| SCHEMBL19696731 | 0.75 | ALDH1A1 (0.44) | USP2ALOX15ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL25132911 | 0.75 | USP2 (0.34) | USP2ALOX15 | |
| SCHEMBL30768041 | 0.75 | MVD (0.39) | USP2ALOX15TSHR | |
| Formic Acid SCHEMBL15822268 | 0.74 | ALDH1A1 (0.37) | ALDH1A1CHRNB2CHRNB4CHRNA4TSHR | |
| SCHEMBL1246998 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL27651914 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | claimed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | claimed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | claimed |
| EP-3227286-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087342-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312207-A1 | Compounds | GRK4, PTGER4, GRK5 | USP2 4439/4885ALOX15 94/4885ALDH1A1 3010/4885 |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | USP2 4706/4885ALOX15 130/4885ALDH1A1 2970/4885 |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | USP2 4348/4885ALOX15 2419/4885ALDH1A1 703/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | USP2 3363/4885ALOX15 1604/4885ALDH1A1 1302/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | USP2 1514/4885ALOX15 4224/4885ALDH1A1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.